Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19)

The summary for the Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19): The purpose of this FOA is to solicit applications for the Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium. The NIAMS, on behalf of the National Institutes of Health, intends to capitalize on recent advances in the science of Patient Reported Outcomes (PROs) to measure the patient experience in clinical care and research in children with a variety of chronic diseases and conditions (e.g., asthma, juvenile arthritis, cystic fibrosis, diabetes, obesity and overweight, chronic kidney disease, inflammatory bowel disease, sickle cell disease, malnutrition, developmental disabilities including attention deficit/hyperactivity disorder and autism spectrum disorder, cerebral palsy and mental illnesses) using the Patient-Reported Outcomes Measurement Information System (PROMIS) tools and approaches coupled with detailed clinical phenotyping and/or biospecimen collection in well-characterized human cohorts. The Patient Reported Outcomes Measurement Information System (PROMIS) is a system of highly reliable, precise measures of patientreported health status for physical, mental, and social wellbeing. PROMIS tools measure what patients are able to do and how they feel by asking questions. PROMIS measures can be used as primary or secondary endpoints in clinical studies of the effectiveness of treatment.

Federal Grant Title:	Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AR-15-014
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.846
CFDA Descriptions:	Arthritis, Musculoskeletal and Skin Diseases Research
Current Application Deadline:	Jun 1, 2015
Original Application Deadline:	Jun 1, 2015
Posted Date:	Mar 6, 2015
Creation Date:	Mar 6, 2015
Archive Date:	Jul 2, 2015
Total Program Funding:	$12,000,000
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:	4
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Special district governments
Independent school districts
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
State governments
Private institutions of higher education
Public and State controlled institutions of higher education
For profit organizations other than small businesses
City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
County governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-15-014.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 ...; • Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 ...; • Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Cli...; • Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed); • NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed); • Collaborative Arthritis and Musculoskeletal and Skin Diseases Science Award (Camssa); • Niams Small Grant Program for New Investigators; • Skin Diseases Research Core Centers
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...